Results 91 to 100 of about 164 (114)

cfDNA fragmentomics for preeclampsia prediction

To investigate whether cfDNA fragmentomic features have the potential to predict early-onset or late-onset PE, we performed WGS of plasma cfDNA (>10X final read depth) from pregnant women with PE (n=109 for early-onset PE, n=333 for late-onset PE) and sampling-gestation-matched healthy controls (n=476).
openaire   +1 more source

Integration of cfDNA fragmentomics for early biliary tract cancer detection.

Journal of Clinical Oncology
4131 Background: Biliary Tract Cancer (BTC) is a highly aggressive malignancy with poor survival outcomes, primarily due to the lack of effective early detection methods and late-stage diagnoses.
Jiwen Wang, Xiaojian Ni, Yuxuan Zheng, Qingxin Xie, Hua Bao, Kun Fan, Dongqin Zhu, Hairong Bao, Ruowei Yang, Chunyan Wang, Bohao Zheng, Shuang Chang, Xiuxiu Xu, Haimeng Tang, Xiaoling Ni, Tao Suo, Xue Wu, Sheng Shen, Han Liu, Houbao Liu   +19 more
openaire   +1 more source

Cell-free DNA fragmentomics and methylomics for thymic epithelial tumors.

Journal of Clinical Oncology
8118 Background: Development of circulating cell-free (cf) DNA assays for cancer detection and monitoring is an area of active research. Limited data are available on the utility of cfDNA for thymic epithelial tumors (TETs).
Michael Daniels, Elizabeth R. Francis, Ling Su, Xiaolin Wu, Elsa Bahiru, Shannon Swift, Christine Feierabend, Susan Sansone, Laercio Lopes DaSilva, Eva Szabo, Chen Zhao, Meredith Jo McAdams, Arun Rajan   +12 more
openaire   +1 more source

A method for early diagnosis of lung cancer from tumor originated DNA fragments using plasma cfDNA methylome and fragmentome profiles

Molecular and Cellular Probes, 2022
Hyun Ju Cho, Sungwoong Jho, Seolbin An
exaly  

Prospective Evaluation of cfDNA Fragmentomes for Lung Cancer Detection

C99. ADVANCES IN BIOMARKERS ACROSS THE LUNG CANCER CONTINUUM, 2023
P.J. Mazzone, K.-K. Wong, J.J. Tsay, A. Vachani, A. Ryan, J. Carey, D. Jakubowski, K. Lumbard, J. Catallini, T. Maddala, P.B. Bach, R. Scharpf, N. Dracopoli, V. Velculescu   +13 more
openaire   +1 more source

Plasma cell-free DNA fragmentomic bioinformatics development

Cell-free DNA (cfDNA) liquid biopsy technology is widely applied in non-invasive prenatal testing (NIPT). Traditional NIPT approaches that only utilize single genetic markers frequently yield inaccurate and unstable testing results, particularly in clinical samples with lower fetal fetal fraction, which limits diagnostic reliability.
openaire   +1 more source

METHODS AND COMPOSITIONS FOR DETECTING CANCER USING FRAGMENTOMICS

2022
KRUGLYAK KRISTINA, MARASS FRANCESCO, TSUI WAI YI   +2 more
openaire   +1 more source

Predicting disease recurrence in limited disease small cell lung cancer using cell-free DNA-based mutation and fragmentome analyses

Translational Lung Cancer Research
Su Yeon Kim
exaly  

Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection—Letter Free

Cancer Discovery
Martin Tammemägi
exaly  

Abstract 1125: Characterizing the cfDNA fragmentome in patients with hepatocellular carcinoma

Cancer Research
Liana Gheorghe, Keerti Boyapati, Adrianna Bartolomucci   +2 more
exaly